Business
Pacira BioSciences Reports First Quarter 2025 Financial Results
-- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in
About this update from Pacira Biosciences, Inc.
[{"type":"text","content":"-- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights Total revenues of $168.9 millionNet product sales of $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°Net income of $4.8 million, or $0.10 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $44.1 million See “Non-GAAP Financial Information” below. “We entered 2025 sharply focused on our 5x30 strategy and our transition into an innovative biopharmaceutical organization,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “The favorable settlement of our EXPAREL patent litigation marks an early and meaningful milestone in our 5x30 strategy, reinforcing our leadership in musculoskeletal pain and adjacencies for years to come. Our recently established EXPAREL exclusivity runway extends to 2039 and provides long-term visibility that empowers us to confidently execute our 5x30 strategy as we generate significant cash flow. With NOPAIN presenting a significant opportunity to expand our EXPAREL market share and drive growth, we believe we are poised to remain the branded market leader and advance much-needed innovation for the 1 in 4 Americans suffering from chronic pain.” “Our confidence in Pacira’s future remains steadfast and the recently announced $300 million stock buyback program underscores our belief in our team, products, and long-term growth outlook,” added Mr. Lee. Recent Business Highlights Settlement of U.S. Patent Litigation for EXPAREL. In April 2025, the company successfully reached a volume-limited settlement agreement with Fresenius Kabi USA and its partners. The agreement recognizes the strength of the EXPAREL intellectual property portfolio with an exclusivity runway that extends to 2039. Limited volumes will begin at a high single-digit percentage of the total volume distributed in the U.S. The limited volume will increase gradually until reaching a maximum percentage in the high thirties for the final three years of the agreement.First Patient Dosed...